ArticleCancer2019
Diagnostic value of biopsy sampling in predicting histology in patients with diffuse malignant pleural mesothelioma.
Article in Cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 47 citations in OpenAlex.
- Reprogramming the tumor microenvironment in mesothelioma: from immune suppression to therapeutic opportunity.Frontiers in immunology · 2026Review
- The genetics of cancer heterogeneity and mesothelioma.Frontiers in oncology · 2026Review
- Mesothelioma: morphologic and immunohistochemical findings.Pathologie (Heidelberg, Germany) · 2024Review
- Contemporary management of mesothelioma.Breathe (Sheffield, England) · 2024Review
- BAP1 Loss, Nuclear Grading, and Nonepithelioid Features in the Diagnosis of Mesothelioma in Italy: Nevermore without the Pathology Report.Journal of personalized medicine · 2024Review
- Perioperative discordance in mesothelioma cell type after pleurectomy/decortication-a possible detrimental effect of neoadjuvant chemotherapy due to epithelial to mesenchymal transition?Interdisciplinary cardiovascular and thoracic surgery · 2023Article
- New Immunohistochemical Markers for Pleural Mesothelioma Subtyping.Diagnostics (Basel, Switzerland) · 2023Article
- Contemporary issues in the surgical management of pleural mesothelioma.Journal of surgical oncology · 2023Review
- New Insights in Pleural Mesothelioma Classification Update: Diagnostic Traps and Prognostic Implications.Diagnostics (Basel, Switzerland) · 2022Review
- Gene Expression Analysis of Biphasic Pleural Mesothelioma: New Potential Diagnostic and Prognostic Markers.Diagnostics (Basel, Switzerland) · 2022Article
- Review
- Survival analysis and development of a prognostic nomogram for patients with malignant mesothelioma in different anatomic sites.Frontiers in oncology · 2022Article
- Multi-site tumor sampling highlights molecular intra-tumor heterogeneity in malignant pleural mesothelioma.Genome medicine · 2021Article
- Contrast-enhanced ultrasound guided pleural biopsy improves diagnostic confidence for pleural based lesions: a 3-year prospective study.BMC pulmonary medicine · 2021Article
- Interobserver Agreement in Histopathological Subtyping of Malignant Pleural Mesotheliomas.Turk patoloji dergisi · 2021Article
- Challenges in lung and thoracic pathology: molecular advances in the classification of pleural mesotheliomas.Virchows Archiv : an international journal of pathology · 2021Review
- Rethought histologic classification of pleural mesothelioma to better treat: go forward from looking back.Translational lung cancer research · 2020Article
- Clinical significance of histologic subtyping of malignant pleural mesothelioma.Translational lung cancer research · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundThe classification of diffuse malignant mesothelioma into epithelioid, biphasic, and sarcomatoid types is based on histologic patterns. The diagnosis is made on biopsies, and because of intratumoral heterogeneity, they may not be representative of the entire tumor. The number and volume of biopsies needed to reach diagnostic accuracy in diffuse malignant mesothelioma and their prognostic value remain unclear.
methodsThis study examined 759 consecutive patients with pleural diffuse malignant mesothelioma treated by pleurectomy/decortication or extrapleural pneumonectomy for the presence of epithelioid and/or sarcomatoid histology and classified both the presurgery biopsies (core-needle or thoracoscopic) and surgical resection specimens. The number and volume of biopsies were correlated with pre- and postsurgery histologies and overall survival.
resultsDiffuse malignant mesothelioma was classified as epithelioid (76%), biphasic (18%), sarcomatoid (5%), or indeterminate (1%) in biopsies and as epithelioid (64%), biphasic (32%), and sarcomatoid (4%) in surgical resection specimens (overall concordance, 80.6%). The positive likelihood ratios were 2.4, 13.6, and 90.1 for biopsies with epithelioid, biphasic, and sarcomatoid histologies, respectively. Concordant histologies between biopsies and resections were associated with a higher number of biopsies (median tissue blocks for concordant histologies vs discordant histologies, 3 vs 2; P < .002) but were less associated with a higher volume (median, 1.2 vs 1.1 cm
conclusionsIn contrast to epithelioid histology, sarcomatoid histology in biopsies is highly accurate. Despite intratumoral heterogeneity, the accuracy of histologic classification increases with the number of tissue blocks examined, emphasizing the diagnostic value of extensive sampling by presurgery biopsies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.